Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer

Journal of Controlled Release

Volumn 197, Issue , 2015, Pages 199-207

  Choi, Seong Ho ^a   Byeon, Hyeong Jun ^a   Choi, Ji Su ^a   Thao, Lequang ^a   Kim, Insoo ^a   Lee, Eun Seong ^b   Shin, Beom Soo ^c   Lee, Kang Choon ^a   Youn, Yu Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Catholic University of Daegu   (South Korea)

Author keywords

Human serum albumin; Inhalation; Nanoparticles; Resistant lung cancer; Self assembly; TRAIL

Indexed keywords

ALDEHYDES; BIOLOGICAL ORGANS; BODY FLUIDS; CONTROLLED DRUG DELIVERY; ENZYME INHIBITION; MAMMALS; NANOPARTICLES; PARTICLE SIZE; SELF ASSEMBLY; TARGETED DRUG DELIVERY; TUMORS;

ALBUMIN NANOPARTICLES; ANTI-TUMOR EFFICACY; APOPTOTIC ACTIVITY; HUMAN SERUM ALBUMINS; INHALATION; LUNG CANCER; PULMONARY DELIVERY; TRAIL;

DISEASES;

ALDEHYDE; DOXORUBICIN; HUMAN SERUM ALBUMIN; NANOPARTICLE; OCTYL ALDEHYDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ALBUMINOID; ANTINEOPLASTIC AGENT; CARBOCYANINE; CY5.5 CYANINE DYE; DRUG CARRIER;

ADSORPTION; AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DISPERSION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RELEASE; HYDROPHOBICITY; LUNG CANCER; MALE; METASTASIS; MOUSE; NONHUMAN; PARTICLE SIZE; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INSTITUTE FOR CANCER RESEARCH MOUSE; LUNG; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADMINISTRATION, INHALATION; ADSORPTION; ALBUMINS; ALDEHYDES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOCYANINES; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, INBRED ICR; NANOPARTICLES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84912076277     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.11.008     Document Type: Article

References (39)

1. N. Wauthoz, P. Deleuze, J. Hecq, I. Roland, S. Saussez, I. Adanja, O. Debeir, C. Decaestecker, V. Mathieu, R. Kiss, and K. Amighi In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy Eur. J. Pharm. Sci. 39 2010 402 411
2. O.B. Garbuzenko, M. Saad, V.P. Pozharov, K.R. Reuhl, G. Mainelis, and T. Minko Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance Proc. Natl. Acad. Sci. U. S. A. 107 2010 10737 10742
3. C.L. Tseng, S.Y. Wu, W.H. Wang, C.L. Peng, F.H. Lin, C.C. Lin, T.H. Young, and M.J. Shieh Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer Biomaterials 29 2008 3014 3022
4. W.H. Roa, S. Azarmi, M.H. Al-Hallak, W.H. Finlay, A.M. Magliocco, and R. Lobenberg Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model J. Control. Release 150 2011 49 55
5. I. Kim, H.J. Byeon, T.H. Kim, E.S. Lee, K.T. Oh, B.S. Shin, K.C. Lee, and Y.S. Youn Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer Biomaterials 33 2012 5574 5583
6. Y.S. Youn, K.C. Lee, Y.H. Bae, K. Na, and E.S. Lee Advanced Pulmonary Delivery of Peptides or Proteins Using Polymeric L. Jorgensen, H.M. Lielsen, DeliveryTechnologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids, and Vaccines 2009 WILEY 228 244
7. A. Sparreboom, C.D. Scripture, V. Trieu, P.J. Williams, T. De, A. Yang, B. Beals, W.D. Figg, M. Hawkins, and N. Desai Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol) Clin. Cancer Res. 11 2005 4136 4143
8. A.T. Chemmanur, and G.Y. Wu Drug evaluation: albuferon-alpha - an antiviral interferon-alpha/albumin fusion protein Curr. Opin. Investig. Drugs 7 2006 750 758
9. F. Kratz DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials Expert Opin. Investig. Drugs 16 2007 855 866
10. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
11. S. Bae, K. Ma, T.H. Kim, E.S. Lee, K.T. Oh, E.S. Park, K.C. Lee, and Y.S. Youn Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types Biomaterials 33 2012 1536 1546
12. S. Yu, P. Yao, M. Jiang, and G. Zhang Nanogels prepared by self-assembly of oppositely charged globular proteins Biopolymers 83 2006 148 158
13. S.H. Lee, D. Heng, W.K. Ng, H.K. Chan, and R.B. Tan Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy Int. J. Pharm. 403 2011 192 200
14. R. Xu, M. Fisher, and R.L. Juliano Targeted albumin-based nanoparticles for delivery of amphipathic drugs Bioconjug. Chem. 22 2011 870 878
15. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems J. Control. Release 157 2012 168 182
16. M.H. Kim, T.R. Billiar, and D.W. Seol The secretable form of trimeric TRAIL, a potent inducer of apoptosis Biochem. Biophys. Res. Commun. 321 2004 930 935
17. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R.G. Goodwin, C.T. Rauch, J.C. Schuh, and D.H. Lynch Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat. Med. 5 1999 157 163
18. J. Vrielink, M.S. Heins, R. Setroikromo, E. Szegezdi, M.M. Mullally, A. Samali, and W.J. Quax Synthetic constrained peptide selectively binds and antagonizes death receptor 5 FEBS J. 277 2010 1653 1665
19. R.M. Pitti, S.A. Marsters, S. Ruppert, C.J. Donahue, A. Moore, and A. Ashkenazi Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J. Biol. Chem. 271 1996 12687 12690
20. A. Almasan, and A. Ashkenazi Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy Cytokine Growth Factor Rev. 14 2003 337 348
21. V.N. Ivanov, A. Bhoumik, and Z. Ronai Death receptors and melanoma resistance to apoptosis Oncogene 22 2003 3152 3161
22. Q.L. Fan, W.Y. Zou, L.H. Song, and W. Wei Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo Cancer Chemother. Pharmacol. 55 2005 189 196
23. S. Wang, W. Ren, J. Liu, G. Lahat, K. Torres, G. Lopez, A.J. Lazar, A. Hayes-Jordan, K. Liu, J. Bankson, J.D. Hazle, and D. Lev TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo Clin. Cancer Res. 16 2010 2591 2604
24. T.R. Singh, S. Shankar, X. Chen, M. Asim, and R.K. Srivastava Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo Cancer Res. 63 2003 5390 5400
25. I. Kim, H.J. Byeon, T.H. Kim, E.S. Lee, K.T. Oh, B.S. Shin, K.C. Lee, and Y.S. Youn Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer Biomaterials 34 2013 6444 6453
26. Y.S. Youn, M.J. Shin, S.Y. Chae, C.H. Jin, T.H. Kim, and K.C. Lee Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) Biotechnol. Lett. 29 2007 713 721
27. H.J. Byeon, S.H. Choi, J.S. Choi, T.H. Kim, E.S. Lee, K.C. Lee, and Y.S. Youn Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model Biomed. Pharmacother. 68 2014 65 69
28. J. Gong, M. Huo, J. Zhou, Y. Zhang, X. Peng, D. Yu, H. Zhang, and J. Li Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles Int. J. Pharm. 376 2009 161 168
29. I. Kim, T.H. Kim, K. Ma, E.S. Lee, D. Kim, K.T. Oh, D.H. Lee, K.C. Lee, and Y.S. Youn Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy Bioconjug. Chem. 21 2010 1513 1519
30. H.J. Byeon, S.H. Choi, J.S. Choi, I. Kim, B.S. Shin, E.S. Lee, E.S. Park, K.C. Lee, and Y.S. Youn Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer Acta Biomater. 10 2014 142 150
31. H.H. Jiang, T.H. Kim, S. Lee, X. Chen, Y.S. Youn, and K.C. Lee PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy Biomaterials 32 2011 8529 8537
32. H. Kim, H. Park, J. Lee, T.H. Kim, E.S. Lee, K.T. Oh, K.C. Lee, and Y.S. Youn Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes Biomaterials 32 2011 1685 1693
33. D.R. Youlden, S.M. Cramb, and P.D. Baade The International Epidemiology of Lung Cancer: geographical distribution and secular trends J. Thorac. Oncol. 3 2008 819 831
34. M. Filipits Mechanisms of cancer: multidrug resistance Drug Discov. Today Dis. Mech. 1 2004 229 234
35. C. Holohan, S. Van Schaeybroeck, D.B. Longley, and P.G. Johnston Cancer drug resistance: an evolving paradigm Nat. Rev. Cancer 13 2013 714 726
36. J.C. Sung, B.L. Pulliam, and D.A. Edwards Nanoparticles for drug delivery to the lungs Trends Biotechnol. 25 2007 563 570
37. C. Lee, J.S. Choi, I. Kim, K.T. Oh, E.S. Lee, E.S. Park, K.C. Lee, and Y.S. Youn Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes Int. J. Nanomedicine 8 2013 2975 2983
38. A. El-Zawahry, J. McKillop, and C. Voelkel-Johnson Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts BMC Cancer 5 2005 2
39. C.C. Jiang, L.H. Chen, S. Gillespie, K.A. Kiejda, N. Mhaidat, Y.F. Wang, R. Thorne, X.D. Zhang, and P. Hersey Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response Cancer Res. 67 2007 5880 5888